HilleVax reported a net loss of $147.3 million for the full year ended December 31, 2024, an increase from $123.6 million in the prior year. The company held $171.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, down from $303.5 million at the end of 2023.
Research and development (R&D) expenses decreased to $78.2 million for the full year 2024, compared to $106.7 million in 2023, primarily due to lower clinical development costs. General and administrative (G&A) expenses increased to $28.8 million in 2024 from $26.7 million in 2023, driven by higher personnel-related costs.
Other income for 2024 was $8.0 million, a decrease from $9.8 million in 2023, primarily due to interest expense incurred on the repayment of the term loan facility during 2024. The company is exploring the potential for continued development of its norovirus vaccine candidates in adults, as well as business development activities and other strategic alternatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.